Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem, Inc.

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing treatments for patients with RAS pathway-driven cancers.

Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. 

Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com.

Twitter:      @VerastemOncolog

Hercules Capital

Oxford Finance LLC

Biotechnology Value Fund

BVF Partners

Longwood Fund

MPM Capital

Advanced Technology Ventures

Astellas Venture Management

Bessemer Venture Partners

Cardinal Partners

Today, in our Q2 2024 financial results and business updates we highlighted the tremendous progress we have made in the second quarter, including initiating our rolling NDA submission for avutometinib and defactinib combination in recurrent LGSOC. Learn about our other highlights below and by reading our press release: https://lnkd.in/esyiVRFV. #VerastemOnc #LGSOC

Join us in congratulating Nathan  (Nate) Sanburn on his promotion to Chief Business Officer. Nate joined Verastem in 2022 and previously served as the SVP of Corporate Development and External Engagement. #VerastemOnc

Congratulations to David Schlaepfer and colleagues for this excellent review of Focal Adhesion Kinase (FAK) inhibitors and the current status of FAK biology just published in the Journal of Cell Science. The article highlights FAK as a master regulator of drug resistance in ovarian cancer, and nicely summarizes ongoing clinical studies with FAK inhibitors including defactinib. This is an exciting time for Verastem as we have initiated our rolling NDA submission for the combination of defactinib with our RAF/MEK clamp avutometinib in recurrent low grade serous ovarian cancer. Appropriately, this review concludes that “after more than 30 years since the discovery of FAK, an [FDA] approval [of the first FAK inhibitor defactinib] might finally be on the near-term horizon”.

The FDA has granted Orphan Drug Designation (ODD) to our investigational combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, for the treatment of pancreatic cancer. At ASCO, we shared positive initial interim results from our ongoing RAMP 205 trial in first-line metastatic pancreatic cancer. We expect to report updated data from RAMP 205 in Q1 2025. Learn more about the designation: https://lnkd.in/eDma4FkG
#VerastemOnc #pancreaticcancer

It’s National Intern Day and we wanted to show appreciation to our intern class of 2024! They have truly shined this summer, making a significant impact across a diverse range of projects. They analyzed manufacturing data, partnered in organizing Verastem’s booth for National Ovarian Cancer Coalition (NOCC) Together in Teal event in September, and created some of our corporate social media content. Watch our intern-created video to learn more about their experiences this summer. #VerastemOnc #thankyou #interns #nationalinternappreciationday #nationalinternday #internappreciationday

We were encouraged to see Verastem Oncology, recipients of PanCAN’s Therapeutic Accelerator Award, present the initial data for their RAMP 205 study at #ASCO24. The goal for this award is to create better therapies for #pancreaticcancer and bring them to patients more quickly. We're thrilled to partner with Verastem to advance progress for this disease!

COM:VERASTEM